EAT-DUTA AndroCoV Trial

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

September 15, 2020

Study Completion Date

October 7, 2020

Conditions
Covid19
Interventions
DRUG

Dutasteride 0.5 mg

Use of dutasteride 0.5mg/day q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.

DRUG

Azithromycin

Azithromycin 500mg/day for 05 days

DRUG

Nitazoxanide

500mg twice daily for 06 days

DRUG

Placebo

Use of placebo q.d. for 30 days or until COVID-19 remission, in recently diagnosed COVID-19 subjects.

Trial Locations (1)

70390-150

Corpometria Institute, Brasília

All Listed Sponsors
lead

Corpometria Institute

OTHER

NCT04729491 - EAT-DUTA AndroCoV Trial | Biotech Hunter | Biotech Hunter